Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Managing cardiovascular risks associated with lifelong TKI therapy in CML

Michael Mauro • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Asciminib

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the management of cardiovascular adverse events (AEs) associated with long-term or lifelong therapy with tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). Prof. Mauro explains that it is important to risk stratify patients when choosing a frontline therapy to minimize the risk of AEs, and to select more tolerable drugs like asciminib in later treatment lines. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding: Novartis, Bristol Myers Squibb, Sun Pharma/Sparc, Takeda; consultancy: Novartis, Bristol Myers Squibb, Takeda, Pfizer.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
2:26
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
Michael Mauro • 18 Dec 2023
1:14
Unmet needs in pediatric CML
Michael Mauro • 22 Oct 2022
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals